Overview
TuHURA Biosciences, Inc. is making waves in the immuno-oncology space. The Tampa, Florida-based company has announced that Dr. James Bianco, President and Chief Executive Officer, will attend two major investor conferences in March 2026. These events give investors a direct opportunity to learn about TuHURA’s breakthrough cancer immunotherapy pipeline.
TuHURA focuses on developing novel therapeutics to overcome resistance to cancer immunotherapy. Resistance — both primary and acquired — is one of the biggest challenges in oncology today. Therefore, TuHURA’s work stands out as critical and timely.
Upcoming Investor Conference Schedule
TuHURA’s leadership team actively engages with the investment community. Consequently, the company plans to present and meet investors at two prominent healthcare and life sciences conferences this March.
Citizens Life Science Conference
Date: Tuesday, March 10, 2026 Time: 4:00 PM ET Format: Live presentation with webcast
Dr. Bianco will present at the Citizens Life Science Conference. Investors can register and view the live presentation directly through the event portal. Furthermore, a recorded archive of the presentation will remain accessible through TuHURA’s investor relations page
This is a strong chance for investors to hear firsthand updates on TuHURA’s Phase 3 clinical programs and pipeline milestones.
Leerink Global Healthcare Conference
Date: Wednesday, March 11, 2026 Format: One-on-one investor meetings
At the Leerink Global Healthcare Conference, TuHURA will hold private one-on-one meetings with qualified investors. To schedule a meeting, interested parties should reach out to their Leerink representative directly. These targeted meetings allow institutional investors to engage personally with company leadership.
About TuHURA Biosciences
TuHURA Biosciences, Inc. is a Phase 3 immuno-oncology company with a mission to tackle a core problem in cancer treatment: resistance to immunotherapy. Most cancer immunotherapies either fail to work initially or stop working over time. TuHURA builds therapies specifically designed to overcome these barriers.
What Sets TuHURA Apart
The company’s pipeline addresses both primary and acquired resistance. This dual focus positions TuHURA uniquely in an increasingly competitive immuno-oncology market. Moreover, TuHURA’s strategic acquisitions expand its platform beyond a single therapeutic approach.
Pipeline Highlights
TuHURA’s lead asset, IFx-2.0, is an innate immune agonist. It targets primary resistance to checkpoint inhibitors — a common failure point in cancer treatment. Notably, TuHURA has launched a Phase 3 randomized, placebo-controlled registration trial of IFx-2.0 as an adjunct to Keytruda® (pembrolizumab) in patients with advanced or metastatic Merkel Cell Carcinoma.
In addition to IFx-2.0, the company acquired TBS-2025 through its merger with Kineta Inc. in June 2025. TBS-2025 is a VISTA-inhibiting monoclonal antibody that now moves into Phase 2 development for relapsed or refractory AML with NPM1 mutations (mutNPM1 r/r AML).
Beyond these programs, TuHURA leverages its proprietary Delta Opioid Receptor technology platform. This platform supports the development of first-in-class bi-specific antibody drug conjugates and antibody peptide conjugates. Together, these target Myeloid Derived Suppressor Cells (MDSCs) to reduce their immune-suppressing effects. As a result, TuHURA aims to prevent T-cell exhaustion and block acquired resistance to both checkpoint inhibitors and cellular therapies.
Clearly, TuHURA is building a diversified and innovative oncology pipeline — one that directly addresses unmet clinical needs.
